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Background: Respiratory Syncytial Virus (RSV) is one of the main causes of respiratory infections during the first
year of life. Very premature infants may contract more severe diseases and ‘late preterm infants’ may also be more
susceptible to the infection.
The aim of this study is to evaluate the risk factors for hospitalization during the first year of life in children born at
different gestational ages in Italy.
Methods: A cohort of 33-34 weeks gestational age (wGA) newborns matched by sex and age with two cohort of
newborns born at 35-37 wGA and > 37 wGA were enrolled in this study for a three-year period (2009-2012).
Hospitalization for bronchiolitis (ICD-9 code 466.1) during the first year of life was assessed through phone
interview at the end of the RSV season (November–March) and at the completion of the first year of life.
Results: The study enrolled 2314 newborns, of which 2210 (95.5 %) had a one year follow-up and were included in
the analysis; 120 (5.4 %) were hospitalized during the first year of life for bronchiolitis. Children born at 33-34 wGA
had a higher hospitalization rate compared to the two other groups. The multivariate analysis carried out on the
entire population associated the following factors with higher rates for bronchiolitis hospitalization: male gender;
prenatal treatment with corticosteroids; prenatal exposure to maternal smoking; singleton delivery; respiratory diseases
in neonatal period; surfactant therapy; lack of breastfeeding; siblings <10 years old; living in crowded conditions and/or
in unhealthy households and early exposure to the epidemic RSV season. When analysis was restricted to preterms
born at 33-34 wGA the following variables were associated to higher rates of bronchiolitis hospitalization: male gender,
prenatal exposure to maternal smoking, neonatal surfactant therapy, having siblings <10 years old, living in crowded
conditions and being exposed to epidemic season during the first three months of life.
Conclusion: Our study identified some prenatal, perinatal and postnatal conditions proving to be relevant and
independent risk factors for hospitalization for bronchiolitis during the first year of life. The combination of these factors
may lead to consider palivizumab prophylaxis in Italy.
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Bronchiolitis is the first cause of hospitalization of infants
in the USA and it is the most frequent lower respiratory
tract disease in preterm infants [1–4].
Infants with chronic lung disease (CLD), congenital
heart disease (CHD), immunodeficiency and neuromuscu-
lar disorders are particularly at high risk of hospitalization
for bronchiolitis [5]. Moreover, preterm infants [6] are
also more prone to these infections due to the impaired
development of the lung and of the immune system. In
particular, it has been observed that prematurity has been
associated to an increased likelihood of hospitalization for
RSV bronchiolitis [1].
Studies performed in Europe and in the USA have also
shown that infants born between 33 and 35 wGA have a
higher risk of hospitalization due to RSV infections than
full-term infants [1, 7, 8]. This population is at risk of de-
veloping severe RSV infection that can result in morbidity
and yield similar expenditures to infants born before 33
wGA [1, 9, 10]. Several studies have found other determi-
nants of bronchiolitis and in particular of severe diseases
caused by RSV [11], however, two of the largest studies
carried out on cohort of infants born at these gestational
ages [12–14] reported inconclusive results, probably due
to the methodologic approach and differences in context
(i.e.social, epidemic, climatic) [8].
In Italy, a multicenter study enrolling over 1200 children
younger than two years hospitalized for lower respiratory
tract infections (LRTI) found that two-thirds of hospitali-
zations occurred in children with low birth weight and
low gestational age, with an incidence 8.5 % in infants
born before 36 weeks vs. 4 % in the general population
[15]. Moreover, among children with bronchiolitis, RSV
infection was particularly frequent in those born at lower
gestational age. Among the patients who were RSV-
positive, 60.0 % were born at a gestational age of 33 weeks;
59.1 % between 34–35 wGA; and 47.4 % at more than 35
wGA [15]. This study found that passive tobacco smoke
exposure increased the rate of hospitalization for RSV in-
fections (RR 1.4). Moreover, RSV positivity was related to
birth order, since it was higher in infants with a larger
number of siblings [15].
The aim of the current study is to evaluate the role of
prenatal, perinatal and postnatal conditions in determin-
ing the risk of hospitalization for bronchiolitis in a large
cohort of preterm with GA 33 weeks or more and full
term newborns.
In addition to that, the analysis of risk factors was fo-
cused on preterm infants born at 33-34 wGA. This popu-
lation of preterm infants, although well documented to be
at high risk of severe RSV infections [1, 7, 8] has been re-
cently crossed out from the revised AAP guidelines [16]
for prophylaxis with palivizumab, a monoclonal human-
ized antibody neutralizing RSV. Two important studies[12–14] analyzed the risk factors for hospitalization in
these preterm infants; however, the analysis of risk factors
in a large Italian birth cohort has not yet been performed.
The determination of national risk factors could improve
the capacity to detect newborns at particularly high risk
for severe respiratory infection and hospitalization that
may be considered for a “tailored” prophylaxis treatment.
In Italy prophylaxis with palivizumab is regulated by
the Italian Neonatology Society guidelines [17], but
they are widely disregarded especially in preterm in-
fants born at 33 wGA or more. The Italian Neonatology
Society is reviewing these recommendations through
the update of the epidemiological data.
The results of the present multicenter study and the
analysis of the risk factors will be considered by the Italian
Neonatology Society for the update of the guidelines.
Methods
This is a multicenter cohort study including consecutive
newborns born between 2009 and 2012. All subjects were
enrolled at birth and followed up for the first year of life.
Thirty Neonatology Units from hospitals with 1000 or
more deliveries per year located in the northern, central,
southern and insular regions of Italy participated in this
study. Ethic Committees of each participating hospital ap-
proved the study protocol. A written consent was obtained
from legal guardians of all patients.
For each enrolled newborn of 33-34 wGA, two further
newborns of the same sex and with the nearest date of birth
were enrolled: one of 35-37 wGA and one of >37 wGA.
Exclusion criteria were life expectancy shorter than six
months; haemodynamically significant congenital heart
diseases and chronic lung diseases (defined as oxygen re-
quiring at 28 days of life [18]); concurrent enrolment in
another trial; programmed or administered RSV prophy-
laxis with palivizumab and inability to follow up at our
center during the study period.
In each center, the enrolling physician filled out a
record with prenatal and perinatal data after checking
inclusion and exclusion criteria, within two days after the
births.
In order to detect possible occurrence of respiratory
infections (leading to hospitalization or not), after enrol-
ment a structured phone interview was carried out twice
with the parents by a trained interviewer from the Italian
National Research Council (CNR). The first interview
was carried out at the end of the epidemic RSV season
(at end of March in Italy [19]) and the second one at
12 months of age. During the phone interview, postnatal
data on potential risk factors such as lack of breastfeeding,
exposure to environmental pollution and/or to passive
cigarette smoke were recorded.
When parents reported hospitalization of the child for
any cause, the enrolling physician collected all the relevant
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clinical record forms.
The primary outcome was the occurrence of
hospitalization/death for bronchiolitis during the first
year of life. Hospitalizations for bronchiolitis were de-
fined according to the hospital discharge form with the
ICD-9 codes 466.1 (acute bronchiolitis).
Table 1 reports the variables registered by the enrolling
physicians and from the interviews concerning neonatal,Table 1 Baseline demographic and clinical characteristic of the enro
wGA groups
33+0d-34+6d (No. 737)
Pregnancy
Assisted reproductive technique 154 (20.9)
Intrauterine growth restriction (IUGR) 82 (11.1)
Mother’s characteristics
Age >40 year 95 (12.9)
Low education 185 (25.1)
Nationality
Italian 654 (88.7)
African 12 (1.6)
Asian 10 (1.4)
Eastern Europe 36 (4.9)
Western Europe 13 (1.8)
Southern America 12 (1.6)
Maternal diseases during pregnancy 275 (37.3)
Treatment with corticosteroids 404 (54.8)
History of respiratory diseases 138 (18.7)
Asthma 49 (6.6)
COPD 12 (1.6)
Eczema 33 (4.5)
Rhinitis 78 (10.6)
Wheezing 1 (0.1)
Prenatal smoke exposure
None 559 (75.8)
To maternal active smoking only 76 (10.3)
To maternal passive smoking only 102 (13.8)
Father’s characteristics
Age >40 year 184 (25.0)
Low education 219 (29.7)
History of respiratory diseases 138 (18.7)
Asthma 51 (6.9)
COPD 8 (1.1)
Eczema 15 (2.0)
Rhinitis 100 (13.6)
All data are reported as No. (%).wGA =weeks of gestational age; yrs = yearsperinatal and postnatal variables potentially associated to
bronchiolitis.
Low level of parental education was defined as no educa-
tion or primary education (vs. secondary or higher).
Presence of maternal diseases during pregnancy was
identified when the mother suffered from chronic con-
ditions or other disorders affecting the pregnancy out-
come such as hypertension, preeclampsia or diabetes
mellitus.lled newborns and of their parents: prenatal conditions
35+0d-37+6d (No. 767) ≥38+0d (No. 706) Total (No. 2210)
90 (11.7) 7 (1.0) 251 (11.4)
58 (7.6) 7 (1.0) 147 (6.7)
91 (11.9) 46 (6.5) 232 (10.5)
184 (24) 131 (18.6) 500 (22.6)
703 (91.7) 655 (92.8) 2012 (91.0)
9 (1.2) 8 (1.1) 29 (1.3)
2 (0.3) 6 (0.8) 18 (0.8)
37 (4.8) 22 (3.1) 95 (4.3)
4 (0.5) 7 (1.0) 24 (1.1)
12 (1.6) 8 (1.1) 32 (1.4)
220 (28.7) 92 (13.0) 587 (26.6)
157 (20.5) 4 (0.6) 565 (25.6)
134 (17.5) 132 (18.7) 404 (18.3)
50 (6.5) 47 (6.7) 146 (6.6)
8 (1.0) 6 (0.8) 26 (1.2)
28 (3.7) 26 (3.7) 87 (3.9)
82 (10.7) 90 (12.7) 250 (11.3)
- 1 (0.1) 2 (0.1)
560 (73.0) 525 (74.4) 1644 (74.4)
93 (12.1) 61 (8.6) 230 (10.4)
114 (14.9) 120 (17.0) 336 (15.2)
203 (26.5) 158 (22.4) 545 (24.7)
261 (34.0) 198 (28.0) 678 (30.7)
158 (20.6) 141 (20.0) 437 (19.8)
48 (6.3) 48 (6.8) 147 (6.7)
14 (1.8) 8 (1.1) 30 (1.4)
12 (1.6) 15 (2.1) 42 (1.9)
133 (17.3) 117 (16.6) 350 (15.8)
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was recorded when the parents reported to have previ-
ously received the diagnosis by other physicians.
A baby was considered small for gestational age
(SGA) if smaller than normal for the gestational age,
most commonly defined as a weight below the 10th percent-
ile for gestational age, according to the Italian neonatal an-
thropometric charts [20].
The presence of siblings in the household of the
child was defined as ≥1 sibling younger than 10 years
living ≥3 days per week in the same house. A crowded
living condition was defined as ≥ 5 inhabitants per house-
hold excluding the study subject and his/her siblings less
than 10 years old.
Breastfeeding was evaluated combining the informa-
tion collected at hospital discharge and that derived
from the two follow up interviews, and was defined as
feeding with maternal milk (exclusively or associated
with formula), either from breast or bottle. Children
were first classified as ‘never breastfed’ or ‘ever breast-
fed’, and children ‘ever breastfed’ were further classified
according to having been fed exclusively with maternal
milk or with both maternal milk and formula together.
Pollution exposure (i.e. residence in the proximity of
intense traffic areas) and indoor humidity exposure (i.e.
visible mold growth) were registered according to inter-
views. Exposure to epidemic season was defined as living
for at least one month of their first three months of life
from November to March.
Sample size was calculated by fixing a predefined preci-
sion of the estimate of the absolute risk of hospitalization
and/or death for RSV-induced or non RSV-induced bron-
chiolitis during the first year of life. Assuming that the risk
of hospitalization for bronchiolitis during the first year of
life was about 7 %, a sample size of 2500 newborns couldTable 2 Baseline demographic and clinical characteristic of the e
conditions
wGA groups
33+0d-34+6d (No. 737) 35
Male gender 382 (51.8) 40
Caesarean delivery 607 (82.4) 52
Singleton delivery 419 (56.9) 55
APGAR score at five minutes <8 42 (5.7) 22
Birth weight [g (mean, SD)] 2031 (380.9) 26
Small for gestational age (SGA) 135 (18.3) 85
Resuscitation after birth 199 (27.0) 10
Neonatal hospitalization 715 (97.0) 43
Respiratory diseases 296 (40.2) 12
Surfactant therapy 48 (6.5) 11
Antibiotics therapy 149 (20.2) 47
All data are reported as No. (%), unless otherwise specified; wGA = weeks of gestatiprovide a 95 % confidence interval (95%CI) of 6.0 to 8.1 %
that is largely consistent with a random error of less than
20 %.
The probability of bronchiolitis-related hospitalization
was considered as a time-dependent variable, and a
survival analysis was carried-out using Cox propor-
tional hazard models to calculate the cumulative time-
dependent risks. Relative risks were estimated as haz-
ard ratios and 95 % confidence limits were derived
from the standard errors of the parameter estimated by
the model.
Crude hazard ratios were calculated for all the consid-
ered variables. Multivariable analyses were carried-out first
on all the variables grouped within each set of pre-, peri-,
and post-natal risk factors. All the variables significantly
associated with the risk of hospitalization for bronchiolitis
in these initial multivariable analyses entered into the final
regression model.
Analyses were carried out using SPSS software package
version 20.0 (IBM Corporation 2010; IBM SPSS Statistics
for Windows).
Results
In a three-year period, 2314 healthy newborns were en-
rolled. Out of those 2210 (95.5 %) of which 1150 male
and 1060 female underwent a one year follow-up and
were included in the analysis; 104 were lost to follow-up
and were excluded. No infants died during the follow-up
period.
Baseline demographic and clinical characteristics of
the enrolled newborns and their parents by gestational
age are reported in Tables 1, 2 and 3.
Conception through assisted reproductive technology,
multiple births, mothers with diseases potentially harmful
for the pregnancy, or who were treated with corticosteroids,nrolled newborns and of their parents: perinatal/neonatal
+0d-37+6d (No. 767) ≥38+0d (No. 706) Total (No. 2210)
0 (52.2) 368 (52.1) 1150 (52.0)
0 (67.8) 262 (37.1) 1389 (62,9)
2 (72) 702 (99.4) 1673 (75.7)
(2.9) 7 (1.0) 71 (3.2)
05.1 (517.1) 3296.1 (423.6) 2635.1 (678.1)
(11.1) 19 (2.7) 239 (10,8)
9 (14.2) 38 (5.4) 346 (15.7)
0 (56.1) 137 (19.4) 1282 (58)
1 (15.8) 23 (3.3) 440 (19.9)
(1.4) 1 (0.1) 60 (2.7)
(6.1) 6 (0.8) 202 (9.1)
onal age
Table 3 Baseline demographic and clinical characteristic of the enrolled newborns and of their parents: postnatal conditions
wGA groups
33+0d-34+6d (No. 737) 35+0d-37+6d (No. 767) ≥38+0d (No. 706) Total (No. 2210)
Presence of siblings
None 472 (64.0) 444 (57.9) 394 (55.8) 1310 (59.3)
≤ 10 year 223 (30.3) 289 (37.7) 280 (39.7) 792 (35.8)
> 10 year 42 (5.7) 34 (4.4) 32 (4.5) 108 (4.9)
Residential crowding 88 (11.9) 86 (11.2) 53 (7.5) 227 (10.3)
Lack of breastfeeding 209 (28.4) 193 (25.2) 80 (11.3) 482 (21.8)
Pollution exposure 77 (10.4) 102 (13.3) 87 (12.3) 266 (12.0)
Exposure to parental smoking 310 (42.1) 320 (41.7) 272 (38.5) 902 (40.8)
Indoor humidity 75 (10.2) 75 (9.8) 72 (10.2) 222 (10)
Exposure to epidemic season 437 (59.3) 474 (61.8) 412 (58.4) 1323 (59.9)
Hospitalization for bronchiolitis 54 (7.3) 41 (5.3) 25 (3.5) 120 (5.4)
All data are reported as No. (%); wGA =weeks of gestational age; yrs = years
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wGA. The babies in this group had a lower birth weight
than newborns born at a longer gestational age and were
more frequently SGA. In addition, they had more fre-
quently neonatal respiratory diseases and/or received more
frequently medical interventions (neonatal resuscitation in
delivery room, hospitalization in neonatal department
and/or in neonatal intensive care unit, surfactant and/or
antibiotic therapy).
Hospitalization for bronchiolitis during the first year of life
Out of the babies who underwent follow-up at 12 months,
120 (5.4 %) were admitted to hospital for bronchiolitis;
65/120 (54 %) hospitalizations occurred within the first
3 months of life and 90/120 (75 %) within the first
6 months of life. The majority of hospital admissions
occurred during the RSV epidemic season and 95/120
(87.5 %) cases occurred in preterm infants, of whom
54/120 (45 %) were born at 33-34 wGA. The majority
of the hospitalizations in this group occurred within
the first 6 months (43/54, 79.6 %) of life, 31/54 (57 %)
within the first 3 months of life.
Of the 120 hospitalized infants, 31/120 (26 %) were
tested for RSV and 26/31 (83 %) were positive.
At univariate analysis (Table 4), the risk estimates
(hazard ratios) for hospitalization for bronchiolitis in-
creased 2 and 1.5 folds respectively for those born at
33-34 and 35-37 wGA compared to the newborns born
at more than 37 wGA. Rates of bronchiolitis occurrence
increased 1.6 folds for male newborns.
The prenatal, neonatal and postnatal conditions found
to be significant at univariate analysis were included in
the multivariate analysis (Table 4 and 5).
At univariate analysis, the prenatal conditions that sig-
nificantly increased the risk of hospitalization for bronchio-
litis were: father history of COPD and prenatal exposure ofthe mother to active or passive smoking. Mother’s comor-
bid conditions (i.e. diabetes, hypertension) and treatment
with corticosteroids showed an increased risk near statis-
tical significance and were included in the multivariable
analyses. Among the neonatal/perinatal risk factors, single-
ton delivery, respiratory diseases, surfactant therapy and
lack of breastfeeding were associated to significantly higher
risks of bronchiolitis admission at univariate analysis. Re-
suscitation with O2 at birth was associated with a 1.4 fold
increased risk but reached only borderline statistical signifi-
cance and was retained for subsequent analyses.
With regard to postnatal/environmental conditions,
having siblings younger than 10 years, crowded living envir-
onment and being exposed to epidemic RSV season were
associated with significantly higher rates of hospitalization.
Residence in proximity of intense vehicular traffic deter-
mined a borderline statistically significant increase of risk
for hospitalization for bronchiolitis and was retained for
further multivariable analyses.
On multivariate analysis, a significant increase of the
risk of hospitalization for bronchiolitis in the entire cohort
was associated to male gender; prenatal treatment with
corticosteroids; tobacco smoke exposure during preg-
nancy; singleton delivery; respiratory disorders and admin-
istration of surfactant at birth, lack of breastfeeding;
siblings younger than 10 years; crowded living conditions
and exposure to household humidity and exposure to epi-
demic season (Table 4).
Subgroup analysis on the group of preterm born at 33-
34 wGA revealed that the significant risk factors partially
differ from the results of the analysis performed on the en-
tire group. At univariate analysis in this particular group,
the significant risk factors for hospitalization for bronchio-
litis are summarized in Table 5. At multivariate analysis
only six factors maintained statistical significance: male
gender; prenatal exposure to maternal smoking; neonatal
Table 4 Relative risks estimates (hazard ratios) according to prenatal, neonatal/perinatal and postnatal/environmental conditions for
hospitalization
Exposures Bronchiolitis hospitalization +/- exposed (%) Multivariable HRa (95%b)
Events/unexposed Events/exoposed [HRc, 95 % CI]
Gender-male 44/1060 (4.2) 76/1150 (6.6) [1.6, 1.1-2.3] 1.6 (1.1-2.4)
Week of gestational age
33-34 vs > 37 25/706 (3.5) 54/737 (7.3) [2.1, 1.3-3.4]
35-37 vs > 37 25/706 (3.5) 41/767 (5.3) [1.5, 0.9-2.5]
Prenatal
Mother’s history of BPCO 117/2184 (5.4) 3/26 (11.5) [2.2, 0.7–6.9]
Mother’s history of eczema 113/2123 (5.3) 7/87 (8.0) [1.6, 0.7–3.4]
Father’s history of BPCO 115/2180 (5.3) 5/30 (16.7) [3.6, 1.5–8.9]
Assisted reproductive technology 115/1959 (5.9) 5/251 (2.0) [0.3, 0.1–0.6]
Treatment with corticosteroids 75/1645 (4.6) 45/565 (8.0) [1.4, 0.9–2.2] 1.6 (1.1–2.4)
Mother’s pregnancy pathologies 78/1623 (4.8) 42/587 (7.2) [1.4, 0.9–2.0]
Prenatal smoke exposure 58/1358 (4.3) 62/852 (7.3) [1.8, 1.2–2.5] 1.6 (1.1–2.3)
Neonatal/Perinatal
Delivery
Singleton 23/537 (4.3) 97/1673 (5.8) [1.9, 1.2–3.0] 1.8 (1.1–2.9)
Resuscitation with O2 95/1911 (5.0) 25/299 (8.4) [1.4, 0.9–2.3)]
Perinatal
Neonatal hospitalization 83/1770 (4.7) 37/440 (8.4) [1.5, 1.0–2.2] 1.6 (1.0–2.5)
Surfactant therapy 109/2150 (5.1) 11/60 (18.3) [3.8, 1.6–5.8] 2.0 (1.1–3.8)
Postnatal (environmental)
Having siblings < 10 years 40/1310 (3.1) 73/792 (9.2) [3.3, 2.2–4.8] 3.0 (2.0–4.5)
≥ 10 years 40/1310 (3.1) 7/108 (6.5) [2.2, 1.0–5.0] 1.9 (0.9–4.4)
Environmental (home) conditions
Residential crowding 93/1983 (4.7) 27/227 (11.9) [2.6, 1.7–3.9] 2.4 (1.5–3.7)
Indoor humidity 101/1988 (5.1) 19/222 (8.6) [1.7, 1.0–2.8] 1.6 (1.0–2.6)
Heating system generating smoke 90/1742 (5.2) 30/468 (6.4) [1.2, 0.8–1.8]
Residence in the proximity of intense vehicular traffic roads 100/1926 (5.2) 20/284 (7.0) [1.4, 0.9–2.3]
Sibilings 63/1414 (4.5) 57/796 (7.2) [1.6, 1.1–2.3]
Lack of breastfeeding 78/1728 (4.5) 42/482 (8.7) [1.8, 1.2-2.6] 1.8 (1.2-2.6)
Passive cigarette smoke exposure 112/2102 (5.3) 8/108 (7.4) [1.5, 0.7–3.1]
Exposed to epidemic RSV season 31/887 (3.5) 89/1323 (6.7) [2.0, 1.3–3.0] 1.9 (1.3–2.9)
aEstimates from a model including all significant variables at gender and weeks of gestational age adjusted analysis
b95 % Confidence Interval
cHazard ratios estimates adjusted for gender and weeks of gestational age
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old, living in crowded conditions and exposure to epi-
demic RSV season (Table 5).
Discussion
This study on infants born at 33 wGA or more provides
an updated report on hospitalizations for bronchiolitis
within an Italian network of thirty Neonatology and
Pediatric Units in a large longitudinal birth cohort.
When analyzing the entire cohort, we found that about5 % of the newborns were admitted to hospital for bron-
chiolitis during their first year of life as well as preterm
infants born at 33-34 wGA had a higher risk of
hospitalization compared to those born at ≥35wGA. The
criteria for hospitalization in Italy were previously pro-
posed by several pediatric scientific society and have
been summarized in an inter-society consensus docu-
ment in 2014 [21]. The indications to hospitalization in-
clude clinical evaluation and analysis of pre-existing risk
factors such as prematurity, congenital heart diseases or
Table 5 Relative risks estimates (hazard ratios) of hospitalization for bronchiolitis in 33+0d-34+6d wGA newborns
Crude HR (95 % CI) Adjusted HR (95 % CI)
Prenatal Conditions
Assisted reproductive technology 0.3 (0.1-0.8)
Prenatal smoke exposure 1.9 (1.1-3.3) 2.0 (1.2-3.5)
Neonatal Conditions
Male gender 1.6 (1.1-2.3) 1.6 (1.0-2.7)
Singleton 1.7 (1.1-3.0)
Apgar in the first 5 min <8 2.2 (1.1-4.9)
Birth weight in g 1.0 (1.0-1.0)
Surfactant therapy 3.8 (2.0-7.4) 3.1 (1.6-6.0)
Antibiotic therapy 2.0 (1.1-3.5)
Postnatal Conditions
Presence of siblings ≤10 year 3.8 (2.1-6.6) 3.2 (1.8-5.7)
Residential crowding 3.0 (1.7-5.5) 2.9 (1.6-5.4)
Indoor humidity 1.9 (1.1-3.8)
Exposure to epidemic season 1.8 (1.0-3.0) 1.8 (1.0-3.3)
wGA =weeks of gestational age; HR = hazard risk; 95 %CI = 95 % confidence interval; yrs = years
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guidelines, the decision to hospitalize an infant to be
derived from the analysis of all the individual criteria.
Male gender, prenatal conditions (treatment with corti-
costeroids and exposure to tobacco smoking), neonatal
conditions (singleton delivery, respiratory diseases, surfac-
tant therapy) and environmental/postnatal conditions (lack
of breastfeeding, having siblings <10 years old, crowded
and unhealthy living conditions and being exposed to
epidemic RSV season) were associated with a significant
increase of hospitalization rate for bronchiolitis in the
entire birth cohort.
The same analysis repeated in the group of infants born
at 33-34 wGA proved that prenatal smoke exposure, male
gender, surfactant therapy, presence of siblings < 10 years,
crowded living conditions and exposure to epidemic
RSV season are statistically significant risk factors for
hospitalization for bronchiolitis.
The results of our analyses were adjusted for wGA,
when referring to the whole cohort, or restricted to 33-
34 wGA infants. According to this, our results point out
that, beyond to postnatal exposures (independent from
wGA), pre- and peri-natal risk factors are associated to
conditions of clinical severity differently prevalent in
premature or non-premature infants, so that prematurity
“per se” is not to be considered a predictor.
Although severe diseases are more common among
children with prematurity, CLD, CHD and other patho-
logic conditions, more than half of babies hospitalized
for RSV infections during the first year of life [1] and
80 % of RSV-related deaths occur among children who
do not have an underlying clinical high-risk condition[4, 22]. This suggests that environmental or other condi-
tions enforce the risk condition due to prematurity and
pre-existing diseases, determining an additional increase
of the risk [23, 24, 10].
Our results only partially agree with other studies. These
disagreements seem intrinsic to the nature of cohort stud-
ies, moreover when carried out in different settings and
with different methodologies. We can hypothesize that
study procedures, different populations, data collection,
variable definitions and follow-up duration may have
played a role in determining partially different results.
Male sex is known to be a risk factor for severe RSV
bronchiolitis [23, 14] with a risk ratio of boys to girls being
1.425:1 [23].
It is also well known that smoking in pregnancy is
associated with reduced lung function of the newborn
[25–27]. In a large case–control study from Denmark
[28] that was designed to evaluate risk factors for RSV
hospitalization in infants younger than 2 years, pre-
natal exposure to smoking was one of the significant
factors on multivariate analysis (odds ratio: 1.56; 95 %
CI: 1.32–1.98).
In our study, prenatal corticosteroid administration
and singleton birth were observed to increase the risk
for hospitalization for bronchiolitis. These data are dis-
cordant with previous studies and require further con-
firmation [29, 30].
A perinatal/neonatal history of respiratory diseases was
observed to be a risk factor for hospitalization, since any
condition impairing the early postnatal development of
the lung predisposes infants to an increased risk of severe
bronchiolitis.
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protective role of breastfeeding on lower respiratory in-
fections. A preliminary analysis conducted on this birth
cohort study reported a clear significant reduction of the
risk of hospitalization for bronchiolitis associated with
breastfeeding (exclusive or in addition to formula milk)
[31], confirmed by the analysis performed in the present
paper on the entire cohort. The studies by Holberg et al.
[32] and Bulkow et al. [33] also described a decreased
risk of RSV hospitalization in breastfeeding infants.
Both crowded living conditions and presence of siblings
appear to be important risk factors for more severe acute
respiratory infections. Reasons include the increased likeli-
hood of exposure to the virus circulation and subsequently
the increased risk for infection. In the Canadian PICNIC
study [14], the presence of preschool-aged siblings was
significantly and independently associated with an in-
creased risk for RSV related hospitalization, and a weaker
association was found with the presence of school-aged
siblings. Crowded living conditions, defined as 5 or more
people living in one household, was also demonstrated to
be a significant risk factor for RSV related hospitalization.
In some contrast, the Spanish FLIP study [13] revealed
that only school-aged siblings and the presence of more
than four additional residents and visitors at home were
risk factors significantly associated with RSV related
hospitalization. In the FLIP-2 study [12], the effect of
school-aged siblings was confirmed, however crowded liv-
ing conditions, identified by the same definition, was not.
The Munich RSV Study Group [7], found that siblings at
day care attendance significantly augmented the risk for
RSV related hospitalization (OR: 3.9; 95 % CI: 1.9-8.3).
Young age at the beginning of the RSV season is a risk
factor for both the development of LRTI as well as
hospitalization due to RSV infection. A review of studies
of RSV hospitalization rates [23] revealed that approxi-
mately 10 % to 28 % of infants hospitalized with RSV are
aged below 6 weeks, 49 % to 70 % below 6 months, and
66 % to 100 % below one year.
Moreover, a recent study [34] analyzing hospitalizations
for acute respiratory infections in infants < 24 months re-
ported that the hospitalization rate was higher during the
first three months of life and then consistently declined.
The greatest risk factor for hospitalization due to RSV
infection appears to be the first few months of life when
coincided with the first half of the RSV season. This data
was also confirmed by two Spanish studies from the IRIS
Group [12, 13] showing that infants with a chronological
age below 10 weeks at the onset of the RSV season were
at higher risk for RSV related hospitalization. In addition,
the majority of hospitalization in our cohort occurred
during the first 6 months of life and this result was con-
firmed focusing the attention in the subgroup of infants
born at 33-34 wGA.This study has some limitations. Firstly, microbio-
logical data to confirm the presence of RSV was avail-
able only in 26 % of the cases of hospitalized infants,
nevertheless with a percentage of RSV positivity higher
than 80 %. Previous Italian data [19] are similar to our
data (near 15 % of observed clinical bronchiolitis in
hospitalized infants were negative when was tested for
RSV).
Moreover, a large Italian study conducted on infants
< 2 years hospitalized for LRTI [15] reported that 40.6 %
of tested infants were RSV positive and the majority of
RSV bronchiolitis occurred in infants ≤ 3 months.
These data suggest that the rate of etiologic misclassifi-
cation can be considered low, also because of the age of
our study subjects being younger than one year, at which
72-84 % of cases of bronchiolitis are RSV positive [35].
In addition, a previous study in the UK estimated that
around 75 % of unspecified bronchiolitis admissions
were RSV related [36]. Globally, it is estimated that only
between 4 % and 28 % of children admitted with bron-
chiolitis are tested for RSV [3].
Considering the statistical analysis, when simultan-
eously analyzing several covariates, issues about overfit-
ting, interaction and correlation may arise. Different not
resolutive approaches and techniques, with relative pros
and cons, may be adopted to address these issues. We
think the potential overfitting was adequately controlled
in our analyses by applying the multi-step selection of
the variables that led to a reduced number of predictors
entering the final models. Interaction is a complex issue
that can be handled with different statistical techniques,
none of them exhaustive, among which one of the mostly
adopted is the building of mutually exclusive levels in new
combined variables, as performed by Escobar et al. [37].
However, in our study no statistically significant inter-
action was found in the final set of predictors, so we think
that the parsimonious models we proposed were appropri-
ate for these analyses.
The strength of this study is that it is the first study to
focus on a large longitudinal Italian birth cohort of new-
borns in order to identify rates and risk factors for
hospitalization for bronchiolitis.
This could allow to improve the indications of prophy-
laxis with palivizumab in infants born at 33 weeks or
more (particularly those born at 33-35wGA), reducing
both the hospitalizations for acute bronchiolitis and its
possible long-term sequelae.
Besides developing particularly serious RSV infections
in the first year of life, preterm infants, even those with-
out CLD, are at higher risk for developing recurrent
wheezing, asthma [38] and allergic sensitization [39–42]
and have persistent abnormal lung function [43]. More-
over in a recent double-blind, placebo-controlled MAKI
trial on healthy preterm infants born at a gestational age
Lanari et al. Italian Journal of Pediatrics  (2015) 41:40 Page 9 of 10of 33 to 35 weeks, Blanken et al. [44] demonstrated that
palivizumab treatment significantly reduces wheezing
days during the first year of life, even after the end of
treatment.Conclusions
The analysis of local epidemiological data and risk factors
involved in RSV-related hospitalization is mandatory in
order to better plan preventive strategy and to develop
updated national guidelines tailored for pediatric high-risk
populations. Epidemiological data and a number of under-
lying risk factors that significantly increase the risk of
severe bronchiolitis and subsequent hospitalization rate
in this group of infants have been identified in our na-
tional birth cohort study, confirming that an infant’s indi-
vidual characteristics and exposure to environmental
factors play an important role in determining the risk of
severe infection and hospitalization, independently from
preterm birth.
The analysis of the weight of each risk factor could
allow to define with greater accuracy the risk for bron-
chiolitis hospitalization for any infant during the first
year of life and to take into account the prophylaxis with
palivizumab through the determination of “tailored”
indications.
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